Journal of Medicinal Chemistry · 2014 · 39 citations · 56 references
MedicineMedicinal ChemistryPharmacologyDrug DesignNeuropharmacologyStructure-activity RelationshipsDopaminergic PharmacologyDrug-receptor InteractionsLead Compound DesignLigand BindingMolecular DockingReceptor PharmacologyDopamine Receptor SubtypesDopaminergic Drug DiscoveryPartial Agonist PotencyRational DesignReceptor-ligand Structural BiologySequence HomologyStructure-based Ligand DesignStructure-based Selectivity Design
Antagonist and partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders. However, development of druglike lead compounds with selectivity for the D3 receptor has been challenging because of the high sequence homology between the D3R and the dopamine D2 receptor (D2R). In this effort, we synthesized a series of acylaminobutylpiperazines incorporating aza-aromatic units and evaluated their binding and functional activities at the D3 and D2 receptors. Docking studies and results from evaluations against a set of chimeric and mutant receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.
56
Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
Ellen Y. T. Chien, Wei Liu, Qiang Zhao et al. · Science · 2010 · 1.1K citations
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
Maria Pilla, Sylvie Perachon, François Sautel et al. · Nature · 1999 · 568 citations
Medicine, Neuroscience, Pharmacology +13